Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

17. Subsequent events:

On October 5, 2017, the Company entered into a subsequent party acknowledgement relating to its participation in the Opioid PMR Consortium (the “OPC”). The participants are member companies, collectively undertaking various observational and clinical studies in order to satisfy certain post-marketing requirements by the FDA as holders of a NDA for extended-release and long-acting opioid analgesics. As a requirement of joining the OPC, the Company was required to pay its share of the previous expenses incurred and funded by the existing member companies. The Company’s pro-rata share of such expenses totals approximately $4.2 million, which will be paid during the fourth quarter of 2017. Ongoing expenses will be shared equally by the member companies and paid monthly for the remainder of 2017 through 2020.